Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's revenue for the
three
months ended in Mar. 2026 was E£638 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was E£2,239 Mil.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Revenue per Share for the
three
months ended in Mar. 2026 was E£12.76.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was E£46.98.
Warning Sign:
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile revenue per share is in decline over the past 12 months.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Revenue Related Terms
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Revenue Chart
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Annual Data
Trend
Jun24
Jun25
Revenue
1,142.58
1,289.58
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Quarterly Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Revenue vs Drug Manufacturers Industry
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£2,239 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) has a Revenue of E£2,239 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile and its competitors.
Is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Revenue too high?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current Revenue is E£2,239 Mil. Overall, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Revenue compare to ZTS and UTHR?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Revenue of E£2,239 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile and its competitors. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current Revenue is E£2,239 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile stock overvalued right now?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) has a current Revenue of E£2,239 Mil. The current Revenue is E£2,239 Mil. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's overall GF Score™ is 31/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH), the current Revenue is E£2,239 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile manufactures and markets pharmaceuticals, medicinal materials, chemical products and surgical threads and medical solutions.
31GF Score
Get the complete analysis for CAI:NIPH
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:NIPH has been successfully added to your 
